BRPI1011145A2 - anticorpo anti-axl - Google Patents
anticorpo anti-axlInfo
- Publication number
- BRPI1011145A2 BRPI1011145A2 BRPI1011145A BRPI1011145A BRPI1011145A2 BR PI1011145 A2 BRPI1011145 A2 BR PI1011145A2 BR PI1011145 A BRPI1011145 A BR PI1011145A BR PI1011145 A BRPI1011145 A BR PI1011145A BR PI1011145 A2 BRPI1011145 A2 BR PI1011145A2
- Authority
- BR
- Brazil
- Prior art keywords
- axl antibody
- axl
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009118725 | 2009-05-15 | ||
| PCT/JP2010/058166 WO2010131733A1 (ja) | 2009-05-15 | 2010-05-14 | 抗axl抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1011145A2 true BRPI1011145A2 (pt) | 2016-03-15 |
Family
ID=43085106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1011145A BRPI1011145A2 (pt) | 2009-05-15 | 2010-05-14 | anticorpo anti-axl |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9340615B2 (pt) |
| EP (1) | EP2431393B1 (pt) |
| JP (1) | JP5669732B2 (pt) |
| KR (1) | KR20120024763A (pt) |
| CN (1) | CN102459344A (pt) |
| AR (1) | AR076875A1 (pt) |
| AU (1) | AU2010248365A1 (pt) |
| BR (1) | BRPI1011145A2 (pt) |
| CA (1) | CA2761891A1 (pt) |
| CL (1) | CL2011002877A1 (pt) |
| CO (1) | CO6460749A2 (pt) |
| CR (1) | CR20110646A (pt) |
| EC (1) | ECSP11011538A (pt) |
| IL (1) | IL216097A0 (pt) |
| MA (1) | MA33405B1 (pt) |
| MX (1) | MX2011012136A (pt) |
| PE (1) | PE20120562A1 (pt) |
| RU (1) | RU2011151069A (pt) |
| SG (1) | SG176074A1 (pt) |
| TW (1) | TW201041595A (pt) |
| WO (1) | WO2010131733A1 (pt) |
| ZA (1) | ZA201108526B (pt) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| EP3415529B1 (en) | 2007-09-26 | 2020-11-04 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
| KR101568051B1 (ko) * | 2007-11-15 | 2015-11-10 | 추가이 세이야쿠 가부시키가이샤 | Ａｎｅｘｅｌｅｋｔｏ에 결합하는 단일클론항체, 및 그의 이용 |
| EP2275443B1 (en) | 2008-04-11 | 2015-12-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
| TWI682995B (zh) | 2009-03-19 | 2020-01-21 | 日商中外製藥股份有限公司 | 抗體恆定區域改變體 |
| TWI638833B (zh) | 2010-11-30 | 2018-10-21 | 中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| TWI654204B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| JP6033293B2 (ja) * | 2011-06-22 | 2016-11-30 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） | 抗Ａｘｌ抗体及びその使用 |
| US9409988B2 (en) | 2011-06-22 | 2016-08-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-Axl antibodies and uses thereof |
| CN103857700A (zh) | 2011-08-26 | 2014-06-11 | 梅里麦克制药股份有限公司 | 串联fc双特异性抗体 |
| ES2732712T3 (es) | 2011-10-31 | 2019-11-25 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera |
| AU2012356894B2 (en) | 2011-12-23 | 2018-01-18 | Araris Biotech Ltd. | Enzymatic conjugation of polypeptides |
| WO2014009426A2 (en) | 2012-07-13 | 2014-01-16 | Innate Pharma | Screening of conjugated antibodies |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| SG11201500873XA (en) | 2012-08-24 | 2015-04-29 | Chugai Pharmaceutical Co Ltd | Fcgriib-specific fc region variant |
| CA2890265C (en) * | 2012-11-05 | 2023-01-17 | Pierre Fabre Medicament | Antigen binding proteins and their use as addressing product for the treatment of cancer |
| EP2916872B1 (en) | 2012-11-09 | 2019-02-27 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
| CA2902505A1 (en) | 2013-03-06 | 2014-09-12 | Merrimack Pharmaceuticals, Inc. | Anti-c-met tandem fc bispecific antibodies |
| WO2014140300A1 (en) | 2013-03-15 | 2014-09-18 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
| TWI636062B (zh) | 2013-04-02 | 2018-09-21 | 中外製藥股份有限公司 | Fc region variant |
| WO2014202773A1 (en) | 2013-06-20 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
| JP6744212B2 (ja) | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | ポリペプチドの酵素的結合 |
| CN104341505A (zh) * | 2013-07-29 | 2015-02-11 | 西藏海思科药业集团股份有限公司 | 对蒙古人种和高加索人种低免疫原性的、抗egfr的人鼠嵌合抗体 |
| TWI522099B (zh) | 2014-06-04 | 2016-02-21 | 中國醫藥大學 | 治療胰臟癌之醫藥配方及其應用 |
| GB201410825D0 (en) | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| GB201410826D0 (en) | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| EP3169706B1 (en) | 2014-07-11 | 2019-12-04 | Genmab A/S | Antibodies binding axl |
| EP3229836B1 (en) * | 2014-12-09 | 2019-11-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Human monoclonal antibodies against axl |
| NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| GB201509338D0 (en) | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
| CA2991805A1 (en) | 2015-07-10 | 2017-01-19 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| MX2018008300A (es) | 2016-01-13 | 2018-09-21 | Genmab As | Formulacion para anticuerpo y conjugado de farmaco del mismo. |
| GB201610902D0 (en) * | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
| BR112019001902A2 (pt) | 2016-08-05 | 2019-07-09 | Chugai Seiyaku Kabushiki Kaisha | composição para profilaxia ou tratamento de doenças relacionadas à il-8 |
| KR101909955B1 (ko) * | 2016-11-28 | 2018-10-19 | 재단법인 목암생명과학연구소 | 신규 항-에이엑스엘 항체 및 이를 포함하는 약학적 조성물 |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| MX2019014572A (es) * | 2017-06-05 | 2020-07-29 | Janssen Biotech Inc | Métodos de ingeniería de carga superficial para la producción de anticuerpos biespecíficos. |
| EP3774904A1 (en) | 2018-04-10 | 2021-02-17 | Genmab A/S | Axl-specific antibodies for cancer treatment |
| CN110483639A (zh) * | 2018-05-15 | 2019-11-22 | 复旦大学 | 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途 |
| CN110540592B (zh) * | 2018-05-29 | 2022-08-09 | 杭州尚健生物技术有限公司 | 结合axl蛋白的抗体及其应用 |
| CN109160941B (zh) * | 2018-09-29 | 2020-09-04 | 未名生物医药有限公司 | 蛋白序列17e11及其用途 |
| WO2020138487A1 (ja) * | 2018-12-28 | 2020-07-02 | 協和キリン株式会社 | ＴｆＲに結合するバイスペシフィック抗体 |
| EP3946453A4 (en) * | 2019-03-29 | 2022-12-07 | Celldex Therapeutics, Inc. | ANTI-AXL ANTIBODIES AND THEIR METHODS OF USE |
| US20220273809A1 (en) | 2019-07-19 | 2022-09-01 | Genmab A/S | Axl antibody-drug conjugates for use in treating cancer |
| GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
| WO2021154156A1 (en) * | 2020-01-31 | 2021-08-05 | Agency For Science, Technology And Research | Anti-axl antibody and uses thereof |
| GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| IL297132A (en) | 2020-04-08 | 2022-12-01 | Bergenbio Asa | axl inhibitors for antiviral therapy |
| GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
| MX2023008744A (es) | 2021-01-29 | 2023-10-02 | Illimis Therapeutics Inc | Molecula de fusion que tiene actividad no inflamatoria inductora de la fagocitosis. |
| GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
| IL289525B2 (en) * | 2021-12-30 | 2023-03-01 | B G Negev Technologies And Applications Ltd At Ben Gurion Univ | Conjugated antibodies for cancer treatment |
| CN117924510B (zh) * | 2024-03-21 | 2024-06-04 | 北京星基贝勤生物科技有限公司 | 靶向egfr和axl的双特异性抗体及其药物偶联物与应用 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
| US5322678A (en) | 1988-02-17 | 1994-06-21 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ES2134212T3 (es) | 1991-04-25 | 1999-10-01 | Chugai Pharmaceutical Co Ltd | Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano. |
| US5468634A (en) | 1991-06-24 | 1995-11-21 | The University Of North Carolina At Chapel Hill | Axl oncogene |
| US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| AU697142B2 (en) | 1993-11-23 | 1998-10-01 | Genentech Inc. | Protein tyrosine kinases named Rse |
| IL107742A0 (en) | 1993-11-24 | 1994-02-27 | Yeda Res & Dev | Chemically-modified binding proteins |
| US8017121B2 (en) | 1994-06-30 | 2011-09-13 | Chugai Seiyaku Kabushika Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| CA2194907A1 (en) | 1994-07-13 | 1996-02-01 | Kouji Matsushima | Reshaped human antibody against human interleukin-8 |
| ATE552012T1 (de) | 1994-10-07 | 2012-04-15 | Chugai Pharmaceutical Co Ltd | Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff |
| PL182089B1 (en) | 1994-10-21 | 2001-11-30 | Chugai Pharmaceutical Co Ltd | Pharmaceutic compositions for treating diseases caused by production of il-6 |
| US5977316A (en) | 1995-01-17 | 1999-11-02 | The Board Of Trustees Of The University Of Kentucky | Monoclonal antibody 1A7 and related polypeptides |
| AU720232B2 (en) | 1996-07-19 | 2000-05-25 | Amgen, Inc. | Analogs of cationic proteins |
| CZ106299A3 (cs) | 1996-09-26 | 1999-08-11 | Chugai Seiyaku Kabushiki Kaisha | Protilátky proti proteinu příbuznému s lidským parathyroidálním hormonem |
| US20070059302A1 (en) | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
| US20020187150A1 (en) | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
| PT1074268E (pt) | 1998-03-17 | 2008-02-28 | Chugai Pharmaceutical Co Ltd | Agentes profilácticos ou terapêuticos para doenças intestinais inflamatórias contendo anticorpos antagonistas do receptor il-6 |
| TR200002885T2 (tr) | 1998-04-03 | 2000-12-21 | Chugai Seiyaku Kabushiki Kaisha | İnsan doku faktörüne (TF) karşı insanlaştırılmış antikor |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP1135415B1 (en) | 1998-12-01 | 2010-08-11 | Facet Biotech Corporation | Humanized antibodies to gamma-interferon |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| US7534605B2 (en) | 1999-06-08 | 2009-05-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| SE9903895D0 (sv) | 1999-10-28 | 1999-10-28 | Active Biotech Ab | Novel compounds |
| AU6627201A (en) | 2000-05-03 | 2001-11-12 | Mbt Munich Biotechnology Gmbh | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites |
| DK2314686T4 (da) | 2000-10-06 | 2023-08-21 | Kyowa Kirin Co Ltd | Celler, der danner antistofsammensætninger |
| WO2002036165A1 (fr) | 2000-10-27 | 2002-05-10 | Chugai Seiyaku Kabushiki Kaisha | Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang |
| HUP0303428A2 (hu) | 2001-03-07 | 2004-01-28 | Merck Patent Gmbh. | Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez |
| UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| AU2002307037B2 (en) | 2001-04-02 | 2008-08-07 | Biogen Idec Inc. | Recombinant antibodies coexpressed with GnTIII |
| UA83791C2 (ru) | 2001-04-13 | 2008-08-26 | Байоджен Айдек Ма Инк. | Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1 |
| WO2003057881A1 (en) * | 2001-12-28 | 2003-07-17 | Chugai Seiyaku Kabushiki Kaisha | Method of stabilizing protein |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| US20060141456A1 (en) | 2002-06-12 | 2006-06-29 | Cynthia Edwards | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
| EP1382969A1 (en) * | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| EP1539947A4 (en) | 2002-08-15 | 2006-09-06 | Epitomics Inc | HUMANIZED RABBIT ANTIBODIES |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| JP2006517109A (ja) | 2003-02-07 | 2006-07-20 | プロテイン デザイン ラブス インコーポレイテッド | アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用 |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| EP2385069A3 (en) | 2003-11-12 | 2012-05-30 | Biogen Idec MA Inc. | Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
| EP1701979A2 (en) | 2003-12-03 | 2006-09-20 | Xencor, Inc. | Optimized antibodies that target the epidermal growth factor receptor |
| AR048210A1 (es) | 2003-12-19 | 2006-04-12 | Chugai Pharmaceutical Co Ltd | Un agente preventivo para la vasculitis. |
| MX370489B (es) | 2004-01-09 | 2019-12-16 | Pfizer | Anticuerpos contra madcam. |
| WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| AR048335A1 (es) | 2004-03-24 | 2006-04-19 | Chugai Pharmaceutical Co Ltd | Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| EP3342782B1 (en) | 2004-07-15 | 2022-08-17 | Xencor, Inc. | Optimized fc variants |
| US20080233131A1 (en) | 2004-09-14 | 2008-09-25 | Richard John Stebbings | Vaccine |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| SG156672A1 (en) | 2004-10-22 | 2009-11-26 | Amgen Inc | Methods for refolding of recombinant antibodies |
| WO2007024249A2 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
| EP1833510A4 (en) | 2004-12-27 | 2010-02-10 | Progenics Pharmaceuticals Neva | ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME |
| CA2595169A1 (en) | 2005-01-12 | 2006-07-20 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
| US8716451B2 (en) | 2005-01-12 | 2014-05-06 | Kyowa Hakko Kirin Co., Ltd | Stabilized human IgG2 and IgG3 antibodies |
| CA2603264C (en) | 2005-04-08 | 2017-03-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor viii |
| EP1789435B1 (en) | 2005-09-12 | 2010-02-24 | Industry Foundation of Chonnam National University | A method for production of mature natural killer cell |
| AU2006297173A1 (en) | 2005-09-29 | 2007-04-12 | Viral Logic Systems Technology Corp. | Immunomodulatory compositions and uses therefor |
| AU2006300234B2 (en) | 2005-10-14 | 2013-01-10 | Chugai Seiyaku Kabushiki Kaisha | Agents for suppressing damage to transplanted islets after islet transplantation |
| US8945558B2 (en) | 2005-10-21 | 2015-02-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for treating myocardial infarction comprising administering an IL-6 inhibitor |
| US7498142B2 (en) | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
| JP2009525048A (ja) | 2006-02-01 | 2009-07-09 | ザ ジョンズ ホプキンス ユニバーシティー | 腫瘍性障害または感染症に対する免疫学的予防法または免疫療法のためのポリペプチド−核酸複合体 |
| TW200808347A (en) | 2006-03-23 | 2008-02-16 | Kirin Brewery | Agonistic antibody directed against human thrombopoietin receptor |
| CN104761637B (zh) * | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| EP2025346B1 (en) | 2006-04-07 | 2016-08-10 | Osaka University | Muscle regeneration promoter |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| EP2155790A1 (en) | 2007-05-31 | 2010-02-24 | Genmab A/S | Method for extending the half-life of exogenous or endogenous soluble molecules |
| EP3415529B1 (en) | 2007-09-26 | 2020-11-04 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| CN101939425B (zh) | 2007-09-26 | 2014-05-14 | 中外制药株式会社 | 抗il-6受体抗体 |
| EP2196541B1 (en) | 2007-09-28 | 2012-11-07 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody having improved kinetics in plasma |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| CA2705164A1 (en) | 2007-11-12 | 2009-05-22 | U3 Pharma Gmbh | Axl antibodies |
| US8898477B2 (en) * | 2007-11-12 | 2014-11-25 | Gemalto Inc. | System and method for secure firmware update of a secure token having a flash memory controller and a smart card |
| KR101568051B1 (ko) * | 2007-11-15 | 2015-11-10 | 추가이 세이야쿠 가부시키가이샤 | Ａｎｅｘｅｌｅｋｔｏ에 결합하는 단일클론항체, 및 그의 이용 |
| CN101952454B (zh) | 2008-02-08 | 2014-06-04 | 米迪缪尼有限公司 | 具有减弱的Fc配体亲和性的抗IFNAR1抗体 |
| EP2275443B1 (en) | 2008-04-11 | 2015-12-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
| TWI682995B (zh) | 2009-03-19 | 2020-01-21 | 日商中外製藥股份有限公司 | 抗體恆定區域改變體 |
| JP5837821B2 (ja) | 2009-09-24 | 2015-12-24 | 中外製薬株式会社 | 抗体定常領域改変体 |
| US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
| BR112012022917A2 (pt) | 2010-03-11 | 2017-01-10 | Pfizer | anticorpos com ligação a antígeno dependente de ph |
-
2010
- 2010-05-14 RU RU2011151069/02A patent/RU2011151069A/ru not_active Application Discontinuation
- 2010-05-14 KR KR1020117029774A patent/KR20120024763A/ko not_active Withdrawn
- 2010-05-14 JP JP2011513382A patent/JP5669732B2/ja active Active
- 2010-05-14 BR BRPI1011145A patent/BRPI1011145A2/pt not_active Application Discontinuation
- 2010-05-14 EP EP10774990.5A patent/EP2431393B1/en active Active
- 2010-05-14 MA MA34445A patent/MA33405B1/fr unknown
- 2010-05-14 TW TW099115414A patent/TW201041595A/zh unknown
- 2010-05-14 CA CA2761891A patent/CA2761891A1/en not_active Abandoned
- 2010-05-14 SG SG2011084050A patent/SG176074A1/en unknown
- 2010-05-14 AU AU2010248365A patent/AU2010248365A1/en not_active Abandoned
- 2010-05-14 PE PE2011001964A patent/PE20120562A1/es not_active Application Discontinuation
- 2010-05-14 CN CN2010800324176A patent/CN102459344A/zh not_active Withdrawn
- 2010-05-14 US US13/320,317 patent/US9340615B2/en active Active
- 2010-05-14 WO PCT/JP2010/058166 patent/WO2010131733A1/ja not_active Ceased
- 2010-05-14 MX MX2011012136A patent/MX2011012136A/es unknown
- 2010-05-14 AR ARP100101702A patent/AR076875A1/es unknown
-
2011
- 2011-11-02 IL IL216097A patent/IL216097A0/en unknown
- 2011-11-11 CO CO11153892A patent/CO6460749A2/es unknown
- 2011-11-15 CL CL2011002877A patent/CL2011002877A1/es unknown
- 2011-11-21 ZA ZA2011/08526A patent/ZA201108526B/en unknown
- 2011-12-02 CR CR20110646A patent/CR20110646A/es not_active Application Discontinuation
- 2011-12-15 EC ECSP11011538 patent/ECSP11011538A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2431393A1 (en) | 2012-03-21 |
| RU2011151069A (ru) | 2013-06-20 |
| WO2010131733A1 (ja) | 2010-11-18 |
| CO6460749A2 (es) | 2012-06-15 |
| WO2010131733A9 (ja) | 2012-01-19 |
| IL216097A0 (en) | 2012-01-31 |
| AR076875A1 (es) | 2011-07-13 |
| MA33405B1 (fr) | 2012-07-03 |
| PE20120562A1 (es) | 2012-06-06 |
| KR20120024763A (ko) | 2012-03-14 |
| MX2011012136A (es) | 2012-04-10 |
| AU2010248365A1 (en) | 2011-12-22 |
| EP2431393B1 (en) | 2018-05-02 |
| ECSP11011538A (es) | 2012-03-30 |
| JPWO2010131733A1 (ja) | 2012-11-08 |
| US9340615B2 (en) | 2016-05-17 |
| EP2431393A4 (en) | 2013-07-17 |
| SG176074A1 (en) | 2011-12-29 |
| JP5669732B2 (ja) | 2015-02-12 |
| TW201041595A (en) | 2010-12-01 |
| CR20110646A (es) | 2012-02-09 |
| US20120121587A1 (en) | 2012-05-17 |
| CN102459344A (zh) | 2012-05-16 |
| CA2761891A1 (en) | 2010-11-18 |
| ZA201108526B (en) | 2012-11-28 |
| CL2011002877A1 (es) | 2012-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2431393A4 (en) | ANTI-AXL ANTIBODY | |
| PT2406284T (pt) | Anticorpos anti-bcma | |
| BRPI0907237A2 (pt) | Anticorpo anti-cldn6 | |
| HRP20171011T1 (hr) | ANTI-eMET ANTITIJELO | |
| BRPI0820073A2 (pt) | Anticorpos anti-axl | |
| HUE036081T2 (hu) | Mirac proteinek | |
| DK2414015T3 (da) | Laryngoskopsystem | |
| DK2411442T4 (da) | Umættet polyesterresin | |
| DE112010002949A5 (de) | Kupplungstastpunkte | |
| EP2518338A4 (en) | TERMINAL | |
| BRPI1008827A2 (pt) | deisobutenizador | |
| BRPI1014968A2 (pt) | subalargador | |
| DE112010002728A5 (de) | Turboinhalator | |
| BRPI0909633A2 (pt) | anticorpos anti-tyrp1 | |
| DE112009005462T8 (de) | Lenkungsssteuervorrichtung | |
| BRPI1008070A2 (pt) | tricianoboratos | |
| DK2483126T3 (da) | Skinnekøretøj | |
| EP2416020A4 (en) | TERMINAL | |
| DE112010004865T8 (de) | Lamellennassreibkupplung | |
| BRPI0912769A2 (pt) | anticorpos anti-pirb | |
| BRPI1010159A2 (pt) | bistuti | |
| DE602010000025D1 (de) | Fahrzeugsitzgurtvorrichtung | |
| BR112012003616A2 (pt) | metilpirroloprimidinacarboxamidas | |
| DE112010002351A5 (de) | Klemmorrichtung | |
| DE112010003843T8 (de) | Lastansteuervorrichtung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |